Stany Zjednoczone - angielski - NLM (National Library of Medicine)

proficient rx - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr

Kanada - angielski - Health Canada

janssen inc - norgestimate; ethinyl estradiol - tablet - 0.25mg; 0.035mg - norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives

Kanada - angielski - Health Canada

janssen inc - norgestimate; ethinyl estradiol - tablet - 0.25mg; 0.035mg - norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives

Kanada - angielski - Health Canada

janssen inc - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol - tablet - 0.18mg; 0.035mg; 0.215mg; 0.035mg; 0.25mg; 0.035mg - norgestimate 0.18mg; ethinyl estradiol 0.035mg; norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives

Kanada - angielski - Health Canada

janssen inc - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; ethinyl estradiol; norgestimate - tablet - 0.215mg; 0.035mg; 0.25mg; 0.035mg; 0.035mg; 0.18mg - norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg; ethinyl estradiol 0.035mg; norgestimate 0.18mg - contraceptives

Kanada - angielski - Health Canada

teva canada limited - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Kanada - angielski - Health Canada

sanis health inc - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

direct rx - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mi

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

proficient rx lp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tabletsshould be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see microbiology (12.4